|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Puleo FR, Maréchal R, Demetter P, Bali MA,
Calomme A, Closset J, Bachet JB, Deviere J and Van Laethem JL: New
challenges in perioperative management of pancreatic cancer. World
J Gastroenterol. 21:2281–2293. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ying H, Dey P, Yao W, Kimmelman AC,
Draetta GF, Maitra A and DePinho RA: Genetics and biology of
pancreatic ductal adenocarcinoma. Genes Dev. 30:355–385. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Moyer MT and Gaffney RR: Pancreatic
adenocarcinoma. N Engl J Med. 371:21402014.PubMed/NCBI
|
|
5
|
Huang S, Zheng J, Huang Y, Song L, Yin Y,
Ou D, He S, Chen X and Ouyang X: Impact of S100A4 expression on
clinicopathological characteristics and prognosis in pancreatic
cancer: A Meta-analysis. Dis Markers. 2016:81373782016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ni S, Wang H, Zhu X, Wan C, Xu J, Lu C,
Xiao L, He J, Jiang C, Wang W and He Z: CBX7 suppresses cell
proliferation, migration, and invasion through the inhibition of
PTEN/Akt signaling in pancreatic cancer. Oncotarget. 8:8010–8021.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chen XX and Bai F: Single-cell analyses of
circulating tumor cells. Cancer Biol Med. 12:184–192.
2015.PubMed/NCBI
|
|
8
|
Hardingham JE, Grover P, Winter M, Hewett
PJ, Price TJ and Thierry B: Detection and clinical significance of
circulating tumor cells in colorectal cancer-20 years of progress.
Mol Med. 21 Suppl 1:S25–S31. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Okegawa T, Itaya N, Hara H, Tambo M and
Nutahara K: Epidermal growth factor receptor status in circulating
tumor cells as a predictive biomarker of sensitivity in
castration-resistant prostate cancer patients treated with
docetaxel chemotherapy. Int J Mol Sci. 17:pii: E2008. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mostert B, Sieuwerts AM, Kraan J, Bolt-de
Vries J, van der Spoel P, van Galen A, Peeters DJ, Dirix LY,
Seynaeve CM, Jager A, et al: Gene expression profiles in
circulating tumor cells to predict prognosis in metastatic breast
cancer patients. Ann Oncol. 26:510–516. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mego M, Giordano A, De Giorgi U, Masuda H,
Hsu L, Giuliano M, Fouad TM, Dawood S, Ueno NT, Valero V, et al:
Circulating tumor cells in newly diagnosed inflammatory breast
cancer. Breast Cancer Res. 17:22015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mego M, Gao H, Cohen EN, Anfossi S,
Giordano A, Tin S, Fouad TM, De Giorgi U, Giuliano M, Woodward WA,
et al: Circulating tumor cells (CTCs) are associated with
abnormalities in peripheral blood dendritic cells in patients with
inflammatory breast cancer. Oncotarget. 8:35656–35668. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gao W, Yuan H, Jing F, Wu S, Zhou H, Mao
H, Jin Q, Zhao J, Cong H and Jia C: Analysis of circulating tumor
cells from lung cancer patients with multiple biomarkers using
high-performance size-based microfluidic chip. Oncotarget.
8:12917–12928. 2017.PubMed/NCBI
|
|
14
|
de Bono JS, Scher HI, Montgomery RB,
Parker C, Miller MC, Tissing H, Doyle GV, Terstappen LW, Pienta KJ
and Raghavan D: Circulating tumor cells predict survival benefit
from treatment in metastatic castration-resistant prostate cancer.
Clin Cancer Res. 14:6302–6309. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chikaishi Y, Yoneda K, Ohnaga T and Tanaka
F: EpCAM-independent capture of circulating tumor cells with a
‘universal CTC-chip’. Oncol Rep. 37:77–82. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Joosse SA, Gorges TM and Pantel K:
Biology, detection, and clinical implications of circulating tumor
cells. EMBO Mol Med. 7:1–11. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Aggarwal C, Meropol NJ, Punt CJ, Iannotti
N, Saidman BH, Sabbath KD, Gabrail NY, Picus J, Morse MA, Mitchell
E, et al: Relationship among circulating tumor cells, CEA and
overall survival in patients with metastatic colorectal cancer. Ann
Oncol. 24:420–428. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liu Y, Yang H, Chen T, Luo Y, Xu Z, Li Y
and Yang J: Silencing of receptor tyrosine kinase ROR1 inhibits
tumor-cell proliferation via PI3K/AKT/mTOR signaling pathway in
lung adenocarcinoma. PLoS One. 10:e01270922015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yamaguchi T, Yanagisawa K, Sugiyama R,
Hosono Y, Shimada Y, Arima C, Kato S, Tomida S, Suzuki M, Osada H
and Takahashi T: NKX2-1/TITF1/TTF-1-induced ROR1 is required to
sustain EGFR survival signaling in lung adenocarcinoma. Cancer
Cell. 21:348–361. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Green JL, Kuntz SG and Sternberg PW: Ror
receptor tyrosine kinases: Orphans no more. Trends Cell Biol.
18:536–544. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cui B, Zhang S, Chen L, Yu J, Widhopf GF
II, Fecteau JF, Rassenti LZ and Kipps TJ: Targeting ROR1 inhibits
epithelial-mesenchymal transition and metastasis. Cancer Res.
73:3649–3660. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Fukuda T, Chen L, Endo T, Tang L, Lu D,
Castro JE, Widhopf GF II, Rassenti LZ, Cantwell MJ, Prussak CE, et
al: Antisera induced by infusions of autologous Ad-CD154-leukemia B
cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a.
Proc Natl Acad Sci USA. 105:3047–3052. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gentile A, Lazzari L, Benvenuti S,
Trusolino L and Comoglio PM: Ror1 is a pseudokinase that is crucial
for Met-driven tumorigenesis. Cancer Res. 71:3132–3141. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cui B, Ghia EM, Chen L, Rassenti LZ,
DeBoever C, Widhopf GF II, Yu J, Neuberg DS, Wierda WG, Rai KR, et
al: High-level ROR1 associates with accelerated disease progression
in chronic lymphocytic leukemia. Blood. 128:2931–2940. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Henry C, Llamosas E, Knipprath-Meszaros A,
Schoetzau A, Obermann E, Fuenfschilling M, Caduff R, Fink D, Hacker
N, Ward R, et al: Targeting the ROR1 and ROR2 receptors in
epithelial ovarian cancer inhibits cell migration and invasion.
Oncotarget. 6:40310–40326. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Borcherding N, Kusner D, Liu GH and Zhang
W: ROR1, an embryonic protein with an emerging role in cancer
biology. Protein Cell. 5:496–502. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Henry CE, Llamosas E, Djordjevic A, Hacker
NF and Ford CE: Migration and invasion is inhibited by silencing
ROR1 and ROR2 in chemoresistant ovarian cancer. Oncogenesis.
5:e2262016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Gal A, Sjöblom T, Fedorova L, Imreh S,
Beug H and Moustakas A: Sustained TGF beta exposure suppresses Smad
and non-Smad signalling in mammary epithelial cells, leading to EMT
and inhibition of growth arrest and apoptosis. Oncogene.
27:1218–1230. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chang K, Kong YY, Dai B, Ye DW, Qu YY,
Wang Y, Jia ZW and Li GX: Combination of circulating tumor cell
enumeration and tumor marker detection in predicting prognosis and
treatment effect in metastatic castration-resistant prostate
cancer. Oncotarget. 6:41825–41836. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Pantel K and Alix-Panabieres C: Functional
studies on viable circulating tumor cells. Clin Chem. 62:328–334.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hamilton G and Rath B: Detection of
circulating tumor cells in non-small cell lung cancer. J Thorac
Dis. 8:1024–1028. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhang S, Cui B, Lai H, Liu G, Ghia EM,
Widhopf GF II, Zhang Z, Wu CC, Chen L, Wu R, et al: Ovarian cancer
stem cells express ROR1, which can be targeted for
anti-cancer-stem-cell therapy. Proc Natl Acad Sci USA.
111:17266–17271. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Reinholz MM, Kitzmann KA, Tenner K,
Hillman D, Dueck AC, Hobday TJ, Northfelt DW, Moreno-Aspitia A, Roy
V, LaPlant B, et al: Cytokeratin-19 and mammaglobin gene expression
in circulating tumor cells from metastatic breast cancer patients
enrolled in North Central Cancer Treatment Group trials,
N0234/336/436/437. Clin Cancer Res. 17:7183–7193. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Hojjat-Farsangi M, Moshfegh A,
Daneshmanesh AH, Khan AS, Mikaelsson E, Osterborg A and Mellstedt
H: The receptor tyrosine kinase ROR1-an oncofetal antigen for
targeted cancer therapy. Semin Cancer Biol. 29:21–31. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Farace F, Massard C, Vimond N, Drusch F,
Jacques N, Billiot F, Laplanche A, Chauchereau A, Lacroix L,
Planchard D, et al: A direct comparison of CellSearch and ISET for
circulating tumour-cell detection in patients with metastatic
carcinomas. Br J Cancer. 105:847–853. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
van de Stolpe A, Pantel K, Sleijfer S,
Terstappen LW and den Toonder JM: Circulating tumor cell isolation
and diagnostics: Toward routine clinical use. Cancer Res.
71:5955–5960. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Danila DC, Anand A, Sung CC, Heller G,
Leversha MA, Cao L, Lilja H, Molina A, Sawyers CL, Fleisher M and
Scher HI: TMPRSS2-ERG status in circulating tumor cells as a
predictive biomarker of sensitivity in castration-resistant
prostate cancer patients treated with abiraterone acetate. Eur
Urol. 60:897–904. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Barriere G, Fici P, Gallerani G, Fabbri F,
Zoli W and Rigaud M: Circulating tumor cells and epithelial,
mesenchymal and stemness markers: Characterization of cell
subpopulations. Ann Transl Med. 2:1092014.PubMed/NCBI
|
|
40
|
Balakrishnan A, Goodpaster T,
Randolph-Habecker J, Hoffstrom BG, Jalikis FG, Koch LK, Berger C,
Kosasih PL, Rajan A, Sommermeyer D, et al: Analysis of ROR1 protein
expression in human cancer and normal tissues. Clin Cancer Res.
23:3061–3071. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Hu J, Locasale JW, Bielas JH, O'Sullivan
J, Sheahan K, Cantley LC, Vander Heiden MG and Vitkup D:
Heterogeneity of tumor-induced gene expression changes in the human
metabolic network. Nat Biotechnol. 31:522–529. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Hou JM, Krebs MG, Lancashire L, Sloane R,
Backen A, Swain RK, Priest LJ, Greystoke A, Zhou C, Morris K, et
al: Clinical significance and molecular characteristics of
circulating tumor cells and circulating tumor microemboli in
patients with small-cell lung cancer. J Clin Oncol. 30:525–532.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Yang J and Weinberg RA:
Epithelial-mesenchymal transition: At the crossroads of development
and tumor metastasis. Dev Cell. 14:818–829. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Wang X, Qiu H, Tang R, Song H, Pan H, Feng
Z and Chen L: miR-30a inhibits epithelialmesenchymal transition and
metastasis in triple-negative breast cancer by targeting ROR1.
Oncol Rep. 39:2635–2643. 2018.PubMed/NCBI
|
